10 Journal of Psychopharmacology
Dittrich A (1998) The standardized psychometric assessment of altered
states of consciousness (ASCS) in humans. Pharmacopsychiatry 31:
Dyck E (2006) ‘Hitting highs at rock bottom’: LSD treatment for alcohol-
ism, 1950–1970. Soc Hist Med 19: 313–329.
Fetzer Institute (1999) Multidimensional Measurement of Religiousness/
Spirituality for Use in Health Research. Kalamazoo, MI: Fetzer
First MB, Spitzer RL, Gibbon M, et al. (1996) Structured Clinical Inter-
view for DSM-IV Axis I Disorders-Patient Edition (Scid-I/P, Version
2.0). New York, NY: Biometrics Research Department, New York
State Psychiatric Institute.
First MB, Spitzer RL, Gibbon M, et al. (1997) Structured Clinical
Interview for DSM-IV Axis I Disorders-Patient Edition. New York,
NY: Biometrics Research Department, New York State Psychiatric
Flannery BA, Volpicelli JR and Pettinati HM (1999) Psychometric prop-
erties of the Penn Alcohol Craving Scale. Alcohol Clin Exp Res 23:
Forcehimes AA (2004) De profundis: Spiritual transformations in Alco-
holics Anonymous. J Clin Psychol 60: 503–517.
Frokjaer VG, Mortensen EL, Nielsen FA, et al. (2008) Frontolimbic
serotonin 2a receptor binding in healthy subjects is associated with
personality risk factors for affective disorder. Biol Psychiatry 63:
Garcia-Romeu AP, Johnson MW and Griffiths RR (2013) Examining the
psychological mechanisms of psilocybin-assisted smoking cessation
treatment: A pilot study. Abstract book. San Diego, CA: CPDD con-
ference, June 16–20, 2013.
George AK, Paul J, Kaimal SB, et al. (2010) Decreased cerebral cor-
tex and liver 5-HT2a receptor gene expression and enhanced ALDH
activity in ethanol-treated rats and hepatocyte cultures. Neurol Res
Ghitza UE, Zhai H, Wu P, et al. (2010) Role of BDNF and GDNF in drug
reward and relapse: A review. Neurosci Biobehav Rev 35: 157–171.
Gresch PJ, Smith RL, Barrett RJ, et al. (2005) Behavioral tolerance to
lysergic acid diethylamide is associated with reduced serotonin-
2a receptor signaling in rat cortex. Neuropsychopharmacology 30:
Griffiths R, Richards W, Johnson M, et al. (2008) Mystical-type experi-
ences occasioned by psilocybin mediate the attribution of personal
meaning and spiritual significance 14 months later. J Psychophar-
macol 22: 621–632.
Griffiths RR, Johnson MW, Richards WA, et al. (2011) Psilocybin occa-
sioned mystical-type experiences: Immediate and persisting dose-
related effects. Psychopharmacology (Berl) 218: 649–665.
Griffiths RR, Richards WA, Mccann U, et al. (2006) Psilocybin can
occasion mystical-type experiences having substantial and sustained
personal meaning and spiritual significance. Psychopharmacology
(Berl) 187: 268–283; discussion 284–292.
Grinspoon L and Balakar JB (1997) Psychedelic Drugs Reconsidered.
New York: The Lindesmith Center.
Grob CS, Danforth AL, Chopra GS, et al. (2011) Pilot study of psilocybin
treatment for anxiety in patients with advanced-stage cancer. Arch
Gen Psychiatry 68: 71–78.
Grof S (2008) LSD Psychotherapy. 4 edn. Ben Lomond, CA: Multidisci-
plinary Association for Psychedelic Studies.
Grof S, Goodman LE, Richards WA, et al. (1973) LSD-assisted psycho-
therapy in patients with terminal cancer. Int Pharmacopsychiatry 8:
Halpern JH (1996) The use of hallucinogens in the treatment of addiction.
Addict Res 4: 177–189.
Hasler F, Grimberg U, Benz MA, et al. (2004) Acute psychological and
physiological effects of psilocybin in healthy humans: A double-
blind, placebo-controlled dose-effect study. Psychopharmacology
(Berl) 172: 145–156.
Hoffer A (1967) A program for treatment of alcoholism: LSD, mal-
varia, and nicotinic acid. In: Abramson HA (ed) The Use of LSD
in Psychotherapy and Alcoholism. Indianapolis: Bobbs-Merrill.
Hollister LE, Shelton J and Krieger G (1969) A controlled comparison of
lysergic acid diethylamide (LSD) and dextroamphetmine in alcohol-
ics. Am J Psychiatry 125: 1352–1357.
Hood RWJ, Ghorbani N, Watson PJ, et al. (2001) Dimensions of the
mysticism scale: Confirming the three-factor structure in the United
States and Iran. J Sci Study Relig 40: 691–705.
James W (1902) The Varieties of Religious Experience. Cambridge, MA:
Harvard University Press.
Johnson BA (2008) Update on neuropharmacological treatments for
alcoholism: Scientific basis and clinical findings. Biochem Pharma-
col 75: 34–56.
Johnson BA, Jasinski DR, Galloway GP, et al. (1996) Ritanserin in the
treatment of alcohol dependence – a multi-center clinical trial. Ritan-
serin Study Group. Psychopharmacology (Berl) 128: 206–215.
Johnson MW, Andrew Sewell R and Griffiths RR (2012) Psilocybin
dose-dependently causes delayed, transient headaches in healthy
volunteers. Drug Alcohol Depend 123: 132–140.
Johnson MW, Garcia-Romeu A, Cosimano MP, et al. (2014) Pilot study
of the 5-HT2AR agonist psilocybin in the treatment of tobacco
addiction. J Psychopharmacol 28: 983–992.
Jones KA, Srivastava DP, Allen JA, et al. (2009) Rapid modulation of
spine morphology by the 5-HT2A serotonin receptor through kali-
rin-7 signaling. Proc Natl Acad Sci U S A 106: 19575–19580.
Kast EC (1966) Pain and LSD-25: A theory of attenuation of anticipation.
In: Solomon D (ed) LSD: The Consciousness-Expanding Drug. New
York, NY: GP Putnam, 239–254.
Kast EC and Collins VJ (1964) Study of lysergic acid diethylamide as an
analgesic agent. Anesth Analg 43: 285–291.
Kometer M, Schmidt A, Bachmann R, et al. (2012) Psilocybin biases
facial recognition, goal-directed behavior, and mood state toward
positive relative to negative emotions through different serotonergic
subreceptors. Biol Psychiatry 72: 898–906.
Krebs TS and Johansen PO (2012) Lysergic acid diethylamide (LSD) for
alcoholism: Meta-analysis of randomized controlled trials. J Psycho-
pharmacol 26: 994–1002.
Kurland AA, Unger S, Shaffer JW, et al. (1967) Psychedelic therapy uti-
lizing LSD in the treatment of the alcoholic patient: A preliminary
report. Am J Psychiatry 123: 1202–1209.
Leuner H (1967) Present state of psycholytic therapy and its possibilities.
In: Abramson HA (ed) The Use of LSD in Psychotherapy and Alco-
holism. Indianapolis: Bobbs-Merrill, pp. 101–116.
Ludwig A, Levine J, Stark L, et al. (1969) A clinical study of LSD treat-
ment in alcoholism. Am J Psychiatry 126: 59–69.
Maclean KA, Johnson MW and Griffiths RR (2011) Mystical experiences
occasioned by the hallucinogen psilocybin lead to increases in the
personality domain of openness. J Psychopharmacol 25: 1453–1461.
Mangini M (1998) Treatment of alcoholism using psychedelic drugs:
A review of the program of research. J Psychoactive Drugs 30:
Martin WR, Sloan JW, Sapira JD, et al. (1971) Physiologic, subjective,
and behavioral effects of amphetamine, methamphetamine, ephed-
rine, phenmetrazine, and methylphenidate in man. Clin Pharmacol
Ther 12: 245–258.
Masters R and Houston J (2000) The Varieties of Psychedelic Experi-
ence: The Classic Guide to the Effects of LSD on the Human Psyche.
Rochester, Vermont: Park Street Press.
Mccrae RR, Costa Jr, PT and Martin TA (2005) The Neo-Pi-3: A
more readable revised neo personality inventory. J Pers Assess
Mcnair DM, Lorr M and Droppleman LF (1981) Profile of Mood States.
San Diego, CA: Educational and Industrial Testing Service.
by guest on January 14, 2015jop.sagepub.comDownloaded from